BIOMAT Database Logo BIOMAT Database Logo

Immunoliposomes As a Promising Antiviral Agent against SARS-CoV-2. 2024

T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. bobik_tanya@mail.ru.

According to the World Health Organization, as of January 3, 2020 to September 13, 2023, there were approximately 23 million confirmed cases of COVID-19 reported in the Russian Federation, about 400 thousand of which were fatal. Considering the high rate of mutation of the RNA-containing virus genome, which inevitably leads to the emergence of new infectious strains (Eris and Pyrola), the search for medicinal antiviral agents remains an urgent task. Moreover, taking into account the actively mutating receptor-binding domain, this task requires fundamentally new solutions. This study proposes a candidate immunoliposomal drug that targets the S protein of SARS-CoV-2 by the monoclonal neutralizing antibody P4A1 and ensures the penetration of a highly active ribonuclease into the virus-infected cell, which degrades, among cellular RNA, viral RNA too. We demonstrate a more than 40-fold increase in the neutralizing activity of the developed drug compared to the free monoclonal neutralizing antibody.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Antiviral Peptides as Promising Therapeutics against SARS-CoV-2.
November 2020, The journal of physical chemistry. B,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease.
March 2022, Journal of chemical information and modeling,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2.
January 2022, Journal of biomaterials science. Polymer edition,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review.
June 2021, Molecules (Basel, Switzerland),
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Antiviral Properties of Alginate-Based Biomaterials: Promising Antiviral Agents against SARS-CoV-2.
August 2021, ACS applied bio materials,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.
November 2023, Asian journal of pharmaceutical sciences,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Hypochlorous acid solution is a potent antiviral agent against SARS-CoV-2.
February 2022, Journal of applied microbiology,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Potential of Azadirachta indica as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2.
January 2022, BioMed research international,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2.
April 2021, Microorganisms,
T V Bobik, and M A Simonova, and N U Rushkevich, and N N Kostin, and G A Skryabin, and V D Knorre, and A A Schulga, and E V Konovalova, and G M Proshkina, and A G Gabibov, and S M Deev
Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2.
March 2021, Biomedical journal,
Copied contents to your clipboard!